Hirudin, an acidic polypeptide secreted by the salivary glands of Hirudo medicinalis (also
known as “Shuizhi” in traditional Chinese medicine), is the strongest natural specific inhibitor …

Factor XIa (FXIa) in the intrinsic pathway of the coagulation process has been proven to be
an effective and safe target for anticoagulant discovery with limited or no bleeding …

Aim To evaluate BAY 2433334, an oral activated factor XI (FXIa) inhibitor, in volunteers.
Methods Phase 1 study of healthy men at a German centre. Part A: randomized, single …

Anticoagulant drugs comprise a specific subcategory of antithrombotic agents that act to
inhibit blood coagulation at various stages, reducing clot development and ultimately …

Anticoagulants are the mainstay for the prevention and treatment of thrombosis. However,
bleeding complications remain a primary concern. Recent advances in understanding the …

Venous thromboembolism (VTE), comprising pulmonary embolism (PE) and deep vein
thrombosis (DVT), poses a significant risk during and after hospitalization, particularly for …

Introduction: Anticoagulation without bleeding is an ideal goal in treating thrombosis,
however, this goal has not been achieved. All current anticoagulants are associated with …

Background Bleeding is a clinically significant issue with all current anticoagulants. Safer
antithrombotic strategies are required. Objectives To investigate the safety …

Abstract Human factor Xa (FXa) is a serine protease of the common coagulation pathway.
FXa is known to activate prothrombin to thrombin, which eventually leads to the formation of …

From the 1940s to 1990s, heparin and warfarin have been the main anticoagulants for the
prevention and treatment of thrombotic events. Since then, LMWHs and fondaparinux …